A Phase 1 Gene Therapy Study for Alpha-1 Antitrypsin Deficiency
Recruiting Phase 1 NCT06996756
Study Description
Investigating a Gene Therapy Treatment for Alpha-1 Antitrypsin Deficiency
Study Details
- Registry ID:
- NCT06996756
- Conditions:
- Alpha 1-Antitrypsin Deficiency
- Phase:
- Phase 1
- Target Enrollment:
- 16 participants
- Start Date:
- Age Range:
- 18–70 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
WCMC Department of Genetic Medicine
New York, New York, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.